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Abstract
PURPOSE—An association of low plasma HDL-cholesterol with risk of breast cancer has been
suggested by multiple studies; the evidence, however, is not conclusive. We examined the possible
association of low HDL-cholesterol with incidence of breast cancer using data from the
Atherosclerosis Risk in Communities Study (ARIC) cohort, a prospective study of a randomly
selected sample of women and men from four US communities.
METHODS—Among 7,575 female members of the ARIC cohort, 359 cases of incident breast cancer
were ascertained during the follow-up from 1987 through 2000. In analysis adjusted for age, race,
body mass index, smoking, and reproductive variables we observed no association of low baseline
HDL-cholesterol (<50 mg/dL) with incident breast cancer in the total sample (HR=1.08(95% CI
0.84, 1.40)) and a modest association (HR=1.67 (95% CI 1.06, 2.63) among women who were pre-
menopausal at baseline. No association was observed among women who were post-menopausal at
baseline. Removal from analysis of the first five years of follow-up did not appreciably change the
observed associations.
CONCLUSION—Results of our study suggest that low HDL-cholesterol among pre-menopausal
women may be a marker of increased breast cancer risk.
MeSH headings
Breast Neoplasms; Cholesterol; HDL; Incidence; Cohort Studies
Correspondence to: Anna M. Kucharska-Newton.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could




Ann Epidemiol. Author manuscript; available in PMC 2009 September 1.
Published in final edited form as:














Identification of modifiable risk factors for breast cancer is hampered by complexity of the
disease and a long lag period between exposure and clinically apparent disease (1,2). Currently
recommended interventions aimed at reducing the risk of breast cancer are weight
management, exercise, reduction in alcohol intake, and, for post-menopausal women,
modifications in hormone replacement therapy regimen. The obesity epidemic has focused
attention on the role of obesity in breast cancer risk. Measures of obesity are consistently
associated with an increased risk of post-menopausal breast cancer (3). Association of obesity
with the risk of pre-menopausal cancer, differ by race, with an inverse association observed
among white women and no association among African-American women (3). Possible
mechanisms explaining the role of adipose tissue in the etiology of breast cancer involve an
increase in estrogen synthesis (4) , increase in insulin levels (4,5), and a decrease in adiponectin
levels (6). Obesity affects the lipid profile (5,7), and decreases levels of HDL-cholesterol.
Recent research suggests that low HDL-cholesterol, a traditional cardiovascular disease risk
factor, may be associated with incidence of cancer at various sites (8) and, as such, may
constitute a potential marker of elevated cancer risk. Of the four prospective studies examining
the association of low HDL-cholesterol with the risk of breast cancer, two have stratified by
menopausal status. One of these (9) suggested that the risk of breast cancer is increased among
pre-menopausal women with low HDL-cholesterol, while the other reported an association of
low HDL-cholesterol with increased risk of post-menopausal breast cancer (10). Studies not
stratified by menopausal status reported mixed results (11,12). This variation in reported results
may reflect differences in study population, study design, as well as selection of analysis
covariates. In addition to these prospective studies, several case-control studies have shown
an association of low HDL-cholesterol with increased breast cancer risk (8,13–16).
The following study, aimed at clarifying the existing evidence, is based on the Atherosclerosis
Risk in Communities (ARIC) cohort, a longitudinal multi-center, bi-racial study with well
defined baseline covariates and a long follow-up period.
Materials and Methods
This study was approved by the appropriate Institutional Review Boards and all participants
provided written consent.
Study description and baseline measurements
The ARIC cohort consists of 15,792 men and women, 45–64 years of age at baseline (1987–
1989), selected as a probability sample from four US communities located in North Carolina,
Mississippi, Minnesota and Maryland (17).
The cohort was examined and risk factor assessed at baseline and at three subsequent triennial
visits through 1998. Risk factors for this analysis were measured at baseline unless indicated
otherwise.
Blood drawn from an antecubital vein into tubes containing EDTA and plasma obtained by
centrifugation at 4°C and stored at −70°C until analysis. Plasma HDL-cholesterol levels were
measured using the method of Warnick et al (18). HDL-cholesterol was coded as a continuous
variable (hazard ratio per one standard deviation), as quartiles of distribution (cutpoints: <45.2
mg/dL, ≥45.2–55.0 mg/dL, ≥55.0–67.4 mg/dL, ≥67.4 mg/dL), and as “high” or “low” based
on the cardiovascular risk clinical cutpoint (50 mg/dL) (19). Plasma triglyceride levels were
determined enzymatically (20) using the Cobas Bioanalyzer (Roche). Body mass index was
calculated as the ratio of weight in kilograms to height in meters_squared.. Waist and hip
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circumferences were measured with the subject standing. Waist-hip ratio was calculated as a
ratio of waist circumference at the umbilicus to the circumference measured at the widest part
of the hips.(21) . Diabetes status (yes/no) at baseline was based on either one of the following
criteria: fasting plasma glucose levels ≥126 mg/dL, non-fasting plasma glucose ≥200 mg/dL,
use of anti-diabetic medication within two weeks of baseline data collection, or self-report of
a physician diagnosis of diabetes. hypertension was defined by current use of antihypertensive,
or systolic blood pressure ≥140 mm Hg, or diastolic blood pressure ≥90 mm Hg. Level of
exercise was based on reported level of sport activity using the Baecke physical activity
questionnaire (22). Alcohol consumption was based on self-report of beer, wine and liquor
consumption. Participants were classified as current, former and never smokers at baseline and
cigarette years of smoking were defined as average number of cigarettes smoked per day times
number of years smoked.
Reproductive variables
Menopausal status was defined as: pre-menopause, peri-menopause, natural post-menopause,
and surgical post-menopause (23). We grouped women who were pre-menopausal (n=1,494)
and peri-menopausal (n=723) at baseline into one category which we labeled “pre-menopause”
and those with both natural and surgical menopause at baseline into a category labeled “post-
menopause”. In order to validate our placement of peri- menopausal women together in a group
with pre-menopausal women we repeated our analyses excluding those cohort members who
were peri-menopausal at baseline.
Information concerning hormone replacement therapy use, number of live births, age at
menarche, and age at menopause was obtained at baseline. Age at first birth and history of
bilateral breast cancer in a first degree relative were obtained by a supplemental questionnaire
collected during telephone follow-up interviews conducted in 1994. Of the 8,710 female
members of the ARIC cohort 8,140 (93%) responded to this questionnaire.
Incident breast cancer cases
Incident breast cancer was ascertained from 1987 through 2000 based on linkages to the
following cancer registries: the Minnesota Cancer Surveillance System, the North Carolina
Cancer Registry, the Washington County (Maryland) Cancer Registry, the (statewide)
Maryland Cancer Registry, and the Mississippi Central Cancer Registry (from 1995). Breast
cancer cases prior to registry initiation (Jackson, Mississippi from 1987 until 1995; Minnesota
from 1987 to 1988) and other possible missed cases were identified through review of all ICD
codes of hospitalizations reported by ARIC study and medical record retrieval. (24).
Statistical analysis
Of 8,710 female ARIC study members at baseline, we excluded those with races other than
white or black (n=25); those who fasted less than 8 hours before venipuncture (n=262), or had
missing data on fasting status (n=44); missing HDL-cholesterol status (n=164); missing
cigarette smoking status (n=9); those with prevalent cancer (n=577); or those missing
information concerning breast cancer incidence (n=117). The final cohort for this analysis
included 7,575 women. In analyses stratified by menopausal status , women with unknown
menopausal status (n=913), as well as women with primary amenorrhea (n=4) were further
excluded, yielding 6,658 as the final number of study participants
Baseline characteristics were summarized as means and proportions of selected variables.
Pairwise t-tests and Pearson’s χ2 coefficients were used to compare means and proportions of
baseline characteristics among the exposed and unexposed groups.
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Associations between baseline HDL-cholesterol and breast cancer incidence were initially
examined using Kaplan-Meier survival estimates. Cox proportional hazard regression of the
association of low HDL-cholesterol (<50 mg/dL) and breast cancer incidence was performed
with evaluation of the following baseline variables for inclusion: age (continuous), race (black,
white), body mass index (continuous), waist-hip ratio diabetes (yes, no), log triglycerides,
smoking status (current, former, never), alcohol intake (grams per week) , sports score
(ordinal), education (less than high school versus high school or greater), age at menarche
(continuous), age at menopause (continuous), and number of live births (continuous). Variables
were considered fro inclusion into the regression model on the basis of existing literature and
retained according to a 10% change-in-estimate criterion (25). Adherence to proportional
hazard assumptions was determined for each covariate and for the overall regression models
on the basis of smoothed plots of Schoenfeld residuals and log-negative log plots (26)
performed before and after stratifying on menopausal status. We evaluated the final fit of the
models by plotting partial Cox-Snell residuals. Tests of the linear trend for the association
between HDL-cholesterol and breast cancer incidence were performed using Cox regression
models with HDL-cholesterol coded as a continuous variable or as an ordinal variable
indicating HDL-cholesterol quartiles.
Interactions between HDL-cholesterol and selected covariates were evaluated using likelihood
ratio tests comparing models with and without multiplicative interaction terms, and by
comparing expected and observed incidence rates assuming multiplicative effects.
All analyses were conducted using STATA statistical software package, version 8.0 (STATA
Corporation, College Station, TX).
Results
There were 359 incident breast cancer events identified in during follow-up from 1987 through
2000. Low baseline HDL-cholesterol (less than 50 mg/dL) was associated with greater current
smoking, higher mean triglyceride levels, higher average BMI and waist-hip-ratio, higher
prevalence of diabetes, and lower use of hormone replacement therapy (Table 1). The ratio of
post-menopausal women to pre-menopausal women was 2.11 for cases (224/106) and 2.00 for
non-cases (4,217/2,111). Eight percent of the cases and 12.3 percent of the non-cases were
missing information on menopausal status.
Sizeable differences between pre-menopausal and post-menopausal women (Table 2) existed
for age, race, triglyceride levels, hormone replacement therapy, diabetes, and education.
We performed a formal evaluation of potential effect modification of the association of low
baseline HDL-cholesterol and incident breast cancer for the following covariates: menopausal
status, smoking (ever versus never), body mass index (using the 25 kg/m2 cutpoint), hormone
use (ever versus never), diabetes status, and race. We found no evidence of effect modification,
except a very modest supra-multiplicative effect of menopausal status (p=0.04). Specifically,
an association between low HDL-cholesterol and incidence of breast cancer was only observed
among women who were pre-menopausal at baseline (Figure 1). This observation agrees with
results of Cox proportional hazard regression analysis which suggests a modest association of
low HDL-cholesterol with increased incidence of breast cancer among women who were pre-
menopausal at baseline (HR=1.67 (95% CI 1.06, 2.63) (Table 3).
Analysis of adjusted hazard rate ratios of breast cancer incidence in quartiles of HDL-
cholesterol levels (Table 3) confirmed the lack of an association in women who were post-
menopausal at baseline and suggested a possible gradient of association in the first three
quartiles of HDL-cholesterol in women who were pre-menopausal at baseline. No was
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observed in either strata of baseline menopausal status when HDL-cholesterol was coded as a
continuous variable.
We addressed the possibility of reverse-causality in the association of low HDL-cholesterol
and breast cancer incidence by removing from our analysis the first five years of follow-up
(Table 3). The adjusted hazard ratio for low versus high HDL-cholesterol was 1.34 (95%CI
0.98, 1.82) for the total sample, 2.25 (95% CI 1.31, 3.86) for the pre-menopausal women and
1.07 (95% CI 0.71, 1.63) for the post-menopausal women.
Sensitivity analyses
Adjustment of analysis for age at first pregnancy slightly strengthened the observed hazard
rate ratios in pre-menopausal women and did not substantially alter the association among post-
menopausal women (hazard rate ratio in fully adjusted model: pre-menopausal women 1.76
(95% CI 1.09, 2.84), post-menopausal women: 0.97 (95% CI 0.67, 1.40)). Further adjustment
for the waist-hip ratio, triglycerides, family history of bilateral breast cancer diagnosis, and use
of cholesterol lowering medications did not appreciably alter the results. We did not observe
any significant differences in the hazard ratios calculated when women who were peri-
menopausal at baseline (n=723) were excluded from the analysis (HR 1.99 (95% CI 1.13, 3.52).
In order to eliminate the potential effect of exogenous estrogens, we repeated our analyses in
a subset of the study sample – women who were pre-menopausal at baseline and who had never
received hormone replacement therapy. The resulting hazard ratio for low HDL-cholesterol,
2.15 (95% CI 1.31, 3.52) was greater than that observed for the full cohort of pre-menopausal
women, although the difference between the two estimates was not statistically significant.
In this cohort of 7,575 women, 913 were missing information concerning menopausal status
(886 women with unknown ovarian status, 27 women with missing data on menopausal status).
A repeat analysis of the association of low HDL-cholesterol with incidence of breast cancer
based on categories of age rather than menopausal status, with 50 years as the age cutpoint,
performed to avoid potential misclassification bias due to the amount of missing data, yielded
results very similar to those obtained using menopausal status data.
There were 18 cases of breast cancer identified in the Jackson, Mississippi, center prior to
establishment of the Mississippi Central Cancer Registry and five cases of incident breast
cancer recorded prior to establishment of the Minnesota Cancer Surveillance System.
Removing those cases from analyses did not appreciably change the effect estimates.
Discussion
This prospective cohort study observed a modest association of low-HDL cholesterol with
increased incidence of breast cancer among women who were pre-menopausal at baseline
(HR=1.67, (95% CI: 1.06, 2.63).
Of the previous prospective studies Moorman et al. (9) reported a modest association of low
HDL-cholesterol with increased risk of breast cancer among pre-menopausal women , while
Furberg et al (10) suggested of an association of low-HDL cholesterol and increased breast
cancer incidence only among post-menopausal women The analysis by Furberg et al. involved
a comparison of relative risks of the disease in quartiles of HDL-cholesterol level. The
relatively small point estimates and small number of cases per quartile do not exclude the
possibility of a modest association among pre-menopausal women as well. The authors of that
study observed an association only among post-menopausal women with body mass index
levels greater than 25 kg/m2. It is possible that, despite adjustment for body mass index, this
observation reflects a residual effect of obesity not captured by the BMI classification,
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especially abdominal obesity (27). Our results appear consistent with data from the study by
Moorman et al (9). The fact that we also observed the association of low HDL-cholesterol and
the risk of breast cancer in a sample in which the first five years of follow-up have been removed
from analysis would suggest independence from the effect of preclinical disease on levels of
HDL-cholesterol.
Our observation of a modest association of low HDL-cholesterol with increased incidence of
breast cancer among women who were pre- and peri-menopausal at baseline, but not among
post-menopausal women, can perhaps be explained in the context of the hormonal regulation
of breast cancer. High endogenous estrogen levels are one of the strongest risk factors for breast
cancer(1). High estrogen levels, observed during pre-menopause, are inversely associated with
low HDL-cholesterol (28). Menopause leads to a decrease in levels of endogenous estrogen,
thereby reducing the potential effect of HDL-cholesterol as a marker of endogenous estrogen
activity.
HDL-cholesterol levels have been found to be inversely associated with levels of insulin-like
growth factor-I (IGF-I) (29–31). Existing studies suggest the presence of an association
between IGF-I among pre-menopausal women and subsequent incidence of breast cancer
during post-menopausal years (32). High premenopausal levels of IGF-I are also associated
with increased breast density during post-menopausal years (33). Increased mammographic
breast density has been found to be independently associated with an increased risk of breast
cancer (34). Our results, suggesting a modest association of low HDL-cholesterol with breast
cancer incidence among women who were pre-menopausal during baseline data collection,
would support those observations.
The 50 mg/dL cutpoint for the dichotomous HDL-cholesterol variable was chosen on the basis
of its common use in cardiovascular disease risk stratification. To our knowledge, this cutpoint
does not have a biological significance associated with the risk of breast cancer. Analysis of
the association of HDL-cholesterol as a continuous variable, as quartiles of HDL-cholesterol
distribution, or through spline regression analysis did not confirm the results we obtained with
the dichotomous HDL-cholesterol classification. Those inconsistencies may have arisen as a
result of a small number of incident cases of breast cancer among women who were pre-
menopausal at baseline (n=106).
The strengths of this study include its prospective design and the biracial aspect of a cohort
drawing from four diverse communities in the United States. HDL-cholesterol measurement
variability in the ARIC study has been estimated to be very small (5%) (35). Limitations of
this study reflect lack of information concerning type and stage of breast cancer, relatively
small number of cases of breast cancer among women who were pre-menopausal at baseline
data collection, and lack of information concerning menopausal status at time of breast cancer
diagnosis. There is no information in the ARIC study concerning screening for breast cancer.
It is possible that detection of breast cancer was different for pre-as compared to post-
menopausal women. It is difficult however to predict the effect any such differential
misclassification would have had on the association of HDL-cholesterol with breast cancer.
In conclusion, we have observed a modest association of low pre-menopausal HDL-cholesterol
with an increased risk of breast cancer. This association was independent of age, age at
menarche, number of live births, race, body mass index, and smoking status, suggesting that
metabolic factors associated with lipid metabolism and transport, may have a role in cancer
development.
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ARIC cohort, Atherosclerosis Risk in Communities cohort; HDL-cholesterol, high density
lipoprotein cholesterol; HR, hazard ratio; 95% CI, 95% confidence interval.
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Table 1
Selected baseline characteristics (mean (standard deviation), or percent) of the ARIC study cohort in relation to baseline
exposure status
Characteristic Exposure status
Total sample Exposed (n=2,682) Unexposed (n=4,893)
(HDL-cholesterol<50 mg/dL) (HDL-cholesterol≥50 mg/dL)
Age 53.7 (5.7) 53.8 (5.8) 53.7 (5.7)
Race, % White 71.0 71.9 70.6
Smoking status:
  Current 24.5 31.9 20.4
  Former 22.3 18.5 24.4
  Never 53.2 49.6 55.2
HDL-cholesterol mg/dL 57.7 (17.1) 41.2 (6.2) 66.7 (14.2)
High triglycerides (≥150 mg/dL) (%) 22.8 42.8 11.9
Medication primarily lowering cholesterol
(%)
2.7 4.6 2.4
All cholesterol lowering medication (%) 27.0 25.3 38.3
Triglycerides (mg/dL) 122.1 (78.6) 162.1 (103.2) 100.2 (48.6)
Body mass index 27.9 (6.1) 29.8 (6.2) 26.8 (5.8)
Waist hip ratio 0.90 (0.08) 0.93 (0.08) 0.88 (0.08)
Diabetes, % 10.5 18 6.4
Education, (% less than high school) 23.2 27.5 20.8
Menopausal status
  Pre- or peri- (%) 29.3 27.4 30.3
  Post- (%) 56.0 59.0 58.4
  Unknown (%) 12.1 13.5 11.2
Average age at menarche 12.9 (1.8) 12.9 (1.7) 12.9 (1.8)
Average age at menopause 35.1 (19.3) 35.3 (19.0) 34.9 (19.5)
Average number of live births 3.3 (2.0) 3.2 (2.0) 3.4 (2.1)
Use of hormone replacement therapy
  Current Estrogen (%) 13.3 7.8 16.3
  Current Estrogen+Progesterone (%) 5.5 2.9 7.0
  Never (%) 63.9 71.2 59.9
  Former (%) 13.9 14.9 13.4
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